Abstract
Helper-dependent adenoviral vectors (HDAd) have been shown to mediate a considerably longer duration of transgene expression than first-generation adenoviral vectors. We have previously shown that transgene expression from HDAd-transduced hepatocytes can persist at high levels for up to 2.6 years in nonhuman primates following a single-vector administration. Because duration of transgene expression and long-term toxicity are critical for risk:benefit assessment, we have continued to monitor these animals. We report here that transgene expression has persisted for the entire observation period of up to 7 years for all animals without long-term adverse effects. However, in all cases, transgene expression level slowly declined over time to less than 10% of peak values by the end of the observation period but remained 2.3-111-fold above baseline values. These results will provide important information for a more informed risk:benefit assessment before clinical application of HDAd.
Original language | English (US) |
---|---|
Pages (from-to) | 761-765 |
Number of pages | 5 |
Journal | Human Gene Therapy |
Volume | 24 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2013 |
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Molecular Biology
- Genetics